|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||50.15 - 50.65|
|52 Week Range||36.81 - 50.65|
|PE Ratio (TTM)||11.99|
|Dividend & Yield||1.64 (3.34%)|
|1y Target Est||N/A|
Promising vaccines just might make this biotech a money machine.
Why Madrigal, Alnylam, and Arbutus Biopharma stocks were this week's biggest biotech winners.
Alnylam (ALNY) and partner Sanofi RNAi therapeutic patisiran met its primary efficacy endpoint and all secondary endpoints in the phase III APOLLO study.